Genmab A/S (NASDAQ:GMAB) Stock Rating Upgraded by BNP Paribas

Genmab A/S (NASDAQ:GMAB) was upgraded by research analysts at BNP Paribas from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Several other equities analysts have also recently commented on GMAB. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research report on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.17.

Genmab A/S Trading Up 4.2 %

Shares of GMAB opened at $19.69 on Tuesday. Genmab A/S has a 12 month low of $18.64 and a 12 month high of $31.88. The firm’s 50 day moving average is $20.68 and its 200-day moving average is $23.21. The stock has a market capitalization of $13.03 billion, a PE ratio of 19.12, a P/E/G ratio of 0.54 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. Equities research analysts predict that Genmab A/S will post 1.25 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Hedge funds and other institutional investors have recently made changes to their positions in the company. Legacy Wealth Asset Management LLC boosted its position in Genmab A/S by 1.1% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 44,979 shares of the company’s stock worth $1,097,000 after buying an additional 471 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Genmab A/S by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock valued at $186,000 after acquiring an additional 827 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC grew its stake in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after purchasing an additional 950 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.